December 21, 2006
Gemin X Biotechnologies to Present at the 25th Annual JPMorgan Healthcare Conference
December 13, 2006
Gemin X's Pan-Bcl-2 Antagonist GX15-070 Permits Rational Combination with Velcade in Mantle Cell Lymphoma
December 12, 2006
Data from Preclinical Studies of Gemin X's GX15-070 Presented in Five Posters at American Society of Hematology Annual Meeting
December 11, 2006
Gemin X Phase 1 Data Show Clinical Activity of GX15-070 in Myelodysplastic Syndromes
November 9, 2006
Review of Clinical Data from Gemin X Biotechnologies' GX15-070 Program Presented at the 24th Annual Chemotherapy Foundation Symposium
September 14, 2006
Gemin X Biotechnologies Initiates Phase 2 Clinical Trial Program for GX15-070 In Myelofibrosis and Hodgkin's Lymphoma
June 5, 2006
Gemin X Pan-Bcl-2 Inhibitor, GX15-070, Shows Biological Activity in Refractory Solid Tumors and Lymphomas
